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Abstract
Objectives—To examine the effects of combination therapy with metformin and paclitaxel in
endometrial cancer cell lines.
Methods—ECC-1 and Ishikawa endometrial cancer cell lines were used. Cell proliferation was
assessed after exposure to paclitaxel and metformin. Cell cycle progression was assessed by flow
cytometry. hTERT expression was determined by real-time RT-PCR. Western immunoblotting
was performed to determine the effect of metformin/paclitaxel on the mTOR pathway.
Results—Paclitaxel inhibited proliferation in a dose-dependent manner in both cell lines with
IC50 values of 1–5 nM and 5–10 nM for Ishikawa and ECC-1 cells, respectively. Simultaneous
exposure of cells to various doses of paclitaxel in combination with metformin (0.5 mM) resulted
in a significant synergistic anti-proliferative effect in both cell lines (Combination Index <1).
Metformin induced G1 arrest in both cell lines. Paclitaxel alone or in combination with metformin
resulted in predominantly G2 arrest. Metformin decreased hTERT mRNA expression while
paclitaxel alone had no effect on telomerase activity. Metformin stimulated AMPK
phosphorylation and decreased phosphorylation of the S6 protein. In contrast, paclitaxel inhibited
AMPK phosphorylation in the ECC-1 cell line and induced phosphorylation of S6 in both cell
lines. Treatment with metformin and paclitaxel resulted in decreased phosphorylation of S6 in
both cell lines but only had an additive effect on AMPK phosphorylation in the ECC-1 cell line.
Conclusions—Metformin potentiates the effects of paclitaxel in endometrial cancer cells
through inhibition of cell proliferation and modulation of the mTOR pathway. This combination
may be a promising targeted therapy for endometrial cancer.
1This work was presented at the 2010 41st Society of Gynecologic Oncology Annual Meeting, San Francisco, CA.
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Endometrial cancer is the fourth most common cancer among women in the United States,
and the death rate from this disease has alarmingly increased by 227% over the past ten
years, paralleling the rise in the obesity epidemic. Type I or those tumors of endometrioid
histology comprise 70–80% of cases and are thought to arise in part from unopposed
estrogen stimulation, either endogenous or exogenous. Women who develop these tumors
are typically peri- or post-menopausal and often have risk factors such as obesity,
hyperlipidemia, diabetes mellitus and insulin resistance, polycystic ovarian syndrome
(PCOS) and hypertension. Obesity, which increases bioavailable estrogen levels by
enhancing the conversion of androstenedione to estrone in peripheral adipose tissue, is a
well-established risk factor for developing type I endometrial cancer and has been estimated
to account for up to 40–90% percent of type I endometrial cancer cases (1–3). Diabetes and
insulin resistance have also emerged as independent risk factors for endometrial cancer (4–
7) and have been linked to a 2–3 fold increased risk of developing this disease.
Metformin is a biguanide drug that is widely used for the treatment of type II diabetes. It is
commonly thought of as an insulin sensitizer because it enhances signaling through the
insulin receptor, leading to an improvement in insulin resistance, followed by a reduction in
circulating insulin levels. More recently, evidence suggests that metformin’s key target of
action is the inhibition of hepatic gluconeogenesis (8), resulting in a secondary decline in
insulin levels. Metformin inhibits complex I activity in the mitochondria (9). This leads to
activation of its downstream target, AMPK, which regulates multiple signaling pathways
controlling cellular proliferation, including inhibition of the mTOR pathway (10). AMPK
regulates energy metabolism and is activated in response to cellular stresses that deplete
cellular energy levels and increase the AMP/ATP ratio (10). AMPK functions to detect
cellular energy and ensure that cell division only proceeds if there are sufficient metabolic
resources to support proliferation. Once activated, AMPK restores cellular energy levels by
stimulating catabolic pathways, such as glucose uptake, glycolysis and fatty acid oxidation
and halting ATP-consuming processes such as fatty acid, cholesterol and protein synthesis.
AMPK activation leads to regulation of multiple downstream pathways involved in the
control of cellular proliferation, including inhibition of the mTOR pathway. Given the
interrelationship between these two pathways, metformin is thought to behave as a novel
mTOR inhibitor and has been shown to dramatically decrease proliferation in a number of
different human cancer cell lines in vitro (11–14). As demonstrated in our previous work in
endometrial cancer cell lines, metformin-mediated AMPK activation decreases cell growth
through inhibition of mTOR and a decrease in phosphorylation of its downstream target, S6
(11). This ultimately results in the inhibition of translation and critical mRNAs involved in
cell cycle progression (13, 15). Treatment with metformin has also been shown to
effectively repress tumor growth in xenograft animal models of breast, prostate and colon
cancer (16–18).
Recent epidemiological evidence suggests that metformin lowers all cancer risk and reduces
cancer incidence and deaths among diabetic patients (19–21). Furthermore, a recent
retrospective cohort study of diabetic patients with early stage breast cancer found that those
women receiving metformin and adjuvant chemotherapy had a higher response rate (22).
This has led to the idea that metformin may have a role in cancer treatment and prevention.
Multiple Phase I-III clinical trials are ongoing, most notably in breast cancer, to further test
metformin’s effects (23, 24).
mTOR inhibitors have shown their efficacy in enhancing the effects of chemotherapeutics
agents in various malignancies (25–29). We have recently demonstrated that the mTOR
Hanna et al. Page 2













inhibitor, rapamycin, potentiates the anti-proliferative effects of paclitaxel in endometrial
cancer cell lines (30). Paclitaxel is a chemotherapeutic agent that stabilizes the microtubules
leading to mitotic arrest and eventual cell death. Given metformin’s inhibitory effects on the
mTOR signaling pathway, we hypothesize that metformin similar to rapamycin may also
serve as a chemosensitizer when combined with paclitaxel. In addition, we have previously
demonstrated that rapamycin and metformin both profoundly suppress telomerase activity
via inhibition of hTERT mRNA expression in endometrial cancer cell lines (11, 31),
constituting another anti-tumorigenic effect shared by these agents. Thus, our goal was to
examine the effects of combination therapy with metformin and paclitaxel in endometrial
cancer cell lines, in regards to proliferation, apoptosis, telomerase regulation and mTOR
signaling. If this combination proves synergistic, metformin and paclitaxel may have great
potential in the treatment of women with advanced or recurrent endometrial cancer, a
disease strongly impacted by obesity and insulin resistance.
MATERIALS AND METHODS
Cell culture and reagents
ECC-1 and Ishikawa endometrial cancer cell lines, were used in these experiments. ECC-1
cells were maintained in RPMI 1640 containing 5% fetal bovine serum, 300 mM L-
glutamine, 5 µg/ml bovine insulin, 10,000 U/ml penicillin and 10,000 µg/ml streptomycin
under 5% CO2. The Ishikawa cells were grown in MEM supplemented with 5% fetal bovine
serum, 300 mM L-glutamine, 5 µg/ml bovine insulin, 10,000 U/ml penicillin and 10,000 µg/
ml streptomycin under 5% CO2.
Metformin, MTT (3-(,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) dye and
RNase A were purchased from Sigma (St. Louis, MO). The anti-cyclin D1, anti-cyclin B1,
anti-phospho-AMPK, anti-pan-AMPK, anti-phospho-S6 and anti-pan-S6 antibodies were
purchased from Cell Signaling (Beverly, MA). Enhanced chemiluminescence Western
blotting detection reagents were purchased from Amersham (Arlington Heights, IL). All
other chemicals were purchased from Sigma.
Cell proliferation assays
The ECC-1 and Ishikawa cells were plated and grown in 96-well plates at a concentration of
6000 cells/well and 8000 cells/well, respectively, for 24 hrs. These cells were subsequently
treated with varying doses of metformin and paclitaxel for 24–72 hrs. Viable cell densities
were determined by metabolic conversion of the dye MTT. MTT (5 mg/ml) was added to
the 96-wells plates at 10 µl/well, followed by an additional hour of incubation. The MTT
reaction was terminated through the addition of 100 µl of DMSO. The results were read by
measuring absorption at 595 nm. The effect of metformin and paclitaxel was calculated as a
percentage of control cell growth obtained from DMSO treated cells grown in the same 96-
well plates. Each experiment was performed in triplicate and repeated three times to assess
for consistency of results.
Flow cytometry
Cells were plated in the appropriate media at 2.5 × 105 in a 6-well plate for 24 hrs. Cells
were subsequently treated with metformin and paclitaxel at varying concentrations for 24
hrs. Cells were collected, washed with PBS, fixed in a 90% methanol solution and then
stored at −20°C until flow cytometric analysis was performed. On the day of analysis, cells
were washed and centrifuged using cold PBS, suspended in 100 µl PBS and 10 µl of RNase
A solution (250 µg/ml) followed by incubation for 30 min at 37°C. After incubation, 110 µl
of PI stain (100 µg/ml) was added to each tube and kept at 4°C for at least 30 min prior to
analysis. Flow cytometric analysis was performed using the CyAn machine (Beckman
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Coulter, Miami, FL). ModFit software (Verity Software House, Topsham, ME) was utilized
for the analysis to control for dead cells and debris. All experiments were performed in
duplicate and repeated twice to assess for consistency of response.
Apoptosis assay
The cells were cultured in 6-well plates at concentrations of 2–4 × 105 cells/well for 24 hrs
and then treated with metformin and paclitaxel at indicated doses for an additional 24 hrs.
Flow cytometry for Annexin-V was performed using the Annexin-V FITC kit (BioVision,
Mountain View, CA). All experiments were performed in duplicate and repeated twice to
assess for consistency of response.
Real-time RT-PCR for hTERT mRNA expression
Total RNA was extracted using the AIQshredder kit (Qiagen, Valencia, CA) and further
purified by the RNeasy Mini-kit (Qiagen, Valencia, CA). The reverse transcription and PCR
reactions were performed using the TaqMan Gold onestep RT-PCR kit in the ABI Prism
7700 Sequence Detection System (Applied Biosystems, Foster City, CA). The cells were
cultured in 6-well plates at concentrations of 3 × 105 cells/well for 24 hrs and then treated
with metformin, paclitaxel or a combination of the two for 48 hrs in 0.5% stripped serum.
Reverse transcription was carried out at 48 °C for 30 min. The PCR conditions consisted of
a 10-min step at 95 °C, 40 cycles at 95 °C for 15 s each and 1 min at 65 °C. A housekeeping
control gene acidic ribosomal phosphoprotein P0 (RPLP0, also known as 36B4) was used as
an internal control to correct for differences in the amount of RNA in each sample. Primers
and fluorogenic probes for hTERT and RPLP0 have been described previously (32). The
standard curve for hTERT was generated by using dilutions of a known amount of cDNA
synthesized by in vitro transcription of a cloned fragment. The normalized level of hTERT
in each sample was estimated by a ratio of the hTERT level to the RPLP0 level, as described
previously (32). Each experiment was performed in triplicate and repeated twice to assess
for consistency of results.
Western immunoblotting
The Ishikawa and ECC-1 cells were plated at 3 × 105 cells/well in 6-well plates in their
corresponding media and then treated for 16 h with metformin, paclitaxel or the combination
of both of these agents. Cell lysates were prepared in RIPA buffer (1% NP40, 0.5 sodium
deoxycholate and 0.1% SDS). Equal amounts of protein were separated by gel
electrophoresis and transferred onto a nitrocellulose membrane. The membrane was blocked
with 5% nonfat dry milk and then incubated with a 1:1000 dilution of primary antibody
overnight at 4 °C. The membrane was then washed and incubated with a secondary
peroxidase-conjugated antibody for 1 hr after washing. Antibody binding was detected using
an enhanced chemiluminescence detection system via the Alpha Innotech Imaging System
(Protein Simple, Santa Clara, CA). After developing, the membrane was stripped and re-
probed using antibody against β-actin and either pan-S6 or pan-AMPK to confirm equal
loading. Western blot films were digitized, and band net intensities were quantified by a
densitometer using the Genegynome Image System (Sygene, MD). Band net intensities were
normalized to β-actin as an internal control. Each experiment was repeated three times to
assess for consistency of results.
Statistical analysis
Results for experiments were normalized to the mean of the control and analyzed using the
student t-test. Differences were considered significant if the p value was less than 0.05
(p<0.05) with a confidence interval of 95%.
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Statistical analysis on synergy was used to evaluate the effects of combined drug treatments.
The results from the MTT assays of each cell line after treatment with metformin alone,
paclitaxel alone and the combination of these two agents were analyzed by the CalcuSyn for
Windows computer program (Biosoft, Cambridge, UK) to determine the presence of
synergy between metformin and paclitaxel.
The software uses a median-effect method, which is a well-established procedure to quantify
the effects of drug combinations and to determine if there is an additive or synergistic effect
of the combination. Such conclusions are based on the calculated combination index (CI) via
the software; CI < 1 means a synergistic activity; whereas a CI value = 1 and a CI > 1 mean
additive and antagonistic effects, respectively.
RESULTS
Synergistic anti-proliferative effects of metformin and paclitaxel
The effects of metformin in combination with paclitaxel on cell proliferation was examined
in the ECC-1 and Ishikawa endometrial cancer cell lines. Both cell lines were exposed to
varying doses metformin and paclitaxel alone, followed by the combination of 0.5 mM
metformin and increasing concentrations of paclitaxel (0.0001 – 100 nM) (Figure 1A and
1B). As anticipated, treatment with paclitaxel resulted in dose-dependent growth inhibition
in both cell lines with IC50 values of 1–5 nM and 5–10 nM for Ishikawa and ECC-1 cells,
respectively. The addition of metformin at 0.5 mM to paclitaxel led to a greater inhibition of
cell proliferation than that of paclitaxel alone (p=0.0007–0.0086 for ECC-1; p=0.0005–
0.0076 for Ishikawa).
Median-effect plot analyses and calculation of the multiple drug effect/CI was performed
using the well-established method of Chou and Talalay (33). Simultaneous exposure of
various doses of paclitaxel in combination with 0.5 mM of metformin on both endometrial
cancer cell lines resulted in a significant synergistic anti-proliferative effect with a CI of <1,
with a range of 0.104 – 0.561 for the ECC-1 cell line (Table 1). Synergy of the metformin
and pacitaxel combination was also confirmed in the Ishikawa cell line for all paclitaxel
concentrations greater than 0.001 nM (CI<1, range of 0.275 to 0.754) (Figure 1C).
Effect of metformin/paclitaxel on cell cycle and apoptosis
To evaluate the underlying mechanism of growth inhibition by metformin and paclitaxel, the
cell cycle profile was analyzed after treating the ECC-1 and Ishikawa endometrial cancer
cell lines with metformin, paclitaxel and the combination of these two agents for 24 hrs. In
Figure 2, metformin (0.1 – 5 mM) resulted in G1 cell cycle arrest in both the ECC-1 and
Ishikawa endometrial cell lines (Figure 2A and 2B). In contrast, paclitaxel (0.1 nM – 100
nM) inhibited cell cycle progression through G2 arrest in both cell lines (Figure 2D and 2E).
When both metformin and paclitaxel were used in combination, the overall effect in both
endometrial cancer cell lines was G2 cell cycle arrest as opposed to G1 arrest (Figure 2 C
and 2F).
Cyclin B1 plays a critical role in the regulation of cell-cycle progression from G2 through M
phase; and thus, accumulates after treatment with paclitaxel (34, 35). The synthesis of cyclin
D1 is initiated during G1 and drives the G1/S phase transition, and metformin has been
shown to decrease cyclin D1 expression (16, 36, 37). Treatment with paclitaxel and
metformin alone resulted in decreased cyclin D1 (28–34% decrease for paclitaxel and 17–
29% decrease for metformin) for both the ECC-1 and Ishikawa cell lines (Figure 2G and
2H). As expected, treatment with paclitaxel led to increased cyclin B1 expression (1.2 fold
for ECC-1 by densitometry and 1.4–1.6 fold for Ishikawa). Treatment with metformin in the
ECC-1 cell line also resulted in increased cyclin B1 expression (1.5–1.6 fold by
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densitometry), but this effect was not seen in the Ishikawa cell line. Treatment with
metformin and paclitaxel in combination resulted in greater induction of cyclin B1 than
either agent alone (3.7 fold for the combination by densitometry versus 1.1 – 1.7 fold as
single agents in the Ishikawa cell line; 1.4 fold for the combination by densitometry versus
1.2 – 1.3 fold as single agents in the ECC-1 cell lines) (Figure 2I). This corresponds to our
cell cycle results in that the overall effect seen with the combination of metformin and
paclitaxel was G2 arrest as opposed to G1 arrest.
The effect of metformin in combination with paclitaxel on apoptosis was evaluated in the
endometrial cancer cell lines. Apopotosis was assessed by flow cytometry, using an
antibody to Annexin V. As demonstrated in Figure 3, paclitaxel induced apoptosis in a dose-
dependent manner (p=0.007–0.032 for ECC-1; P=0.005–0.031 for Ishikawa). Metformin
also induced apoptosis in these cell lines at higher doses of treatment (2–5 mM) (p=0.022–
0.041 for ECC-1, p=0.035–0.055 for Ishikawa). The combination of metformin (1 mM) and
paclitaxel (10 nM – 100 nM) resulted in increased apoptosis, over that of either alone
(p=0.031–0.041 for ECC-1; p=0.020–0.037 for Ishikawa). These results indicate that
metformin enhances the efficacy of paclitaxel by potentially two mechanisms - increasing
G2 arrest and stimulating paclitaxel-induced apoptosis.
Effect of metformin/paclitaxel on hTERT mRNA level
The maintenance of telomere length via the expression of telomerase is vital to the ability of
cancer cells to remain proliferative. hTERT expression is the rate-limiting determinant of the
enzymatic activity of human telomerase and is thought to be a sensitive marker of
telomerase function. Real-time RT-PCR was used to quantify hTERT mRNA expression in
the endometrial cancer cell lines. Treatment with metformin alone decreased hTERT mRNA
expression as compared to control (p=0.05 for ECC-1; p=0.0004 for Ishikawa), whereas
hTERT mRNA expression was not affected by paclitaxel treatment alone. However, the
combination of metformin (1 mM) and increasing concentrations of paclitaxel (1 – 10 nM)
resulted in a dose dependent decrease in hTERT mRNA expression (p=0.006–0.028 for
ECC-1; p = .0041–0.057 for Ishikwa). This was observed in both endometrial cancer cell
lines used (Figure 4). This data suggests that the combination of metformin and paclitaxel
inhibits telomerase activity by rapidly decreasing hTERT mRNA levels.
The effect of metformin and metformin/paclitaxel on the mTOR pathway
To investigate the molecular mechanisms underlying the synergistic anti-proliferative effect
between metformin and paclitaxel, we characterized the effect of this combination treatment
on relevant cell signaling targets. Metformin induced AMPK phosphorylation in a dose-
dependent manner in both endometrial cancer cell lines whereas it had no effect on the total
AMPK (Figure 5A). Per densitometric analysis, phosphorylation of AMPK was increased
1.6 – 5.4 fold for the ECC-1 cell line and 1.1 – 3.2 fold for the Ishikawa cell line. Paclitaxel
induced AMPK phosphorylation in the ECC-1 cell line (1.7 – 2.3 fold by densitometry)
(Figure 5B) but had no effect on AMPK phosphorylation in the Ishikawa cell line (Figure
5B). The combination of metformin (1 mM) and paclitaxel (1 nM) induced AMPK
phosphorylation in the ECC-1 cell line that was more than that induced by either agent alone
(3.2 fold for the combination by densitometry versus 1.2 – 1.6 fold as single agents) (Figure
5C). This additive effect of metformin and paclitaxel treatment on AMPK phosphorylation
was not demonstrated in the Ishikawa cell line (Figure 5C).
Previous studies suggest that p70S6K is a downstream target of the mTOR pathway (38).
p70S6K kinase directly phosphorylates the 40S ribosomal protein S6, which results in
enhanced synthesis of proteins that contain a polypyrimidine tract in the 50-untranslated
region (38). Therefore, we evaluated the effect of metformin and paclitaxel on the
Hanna et al. Page 6













phosphorylation of the S6 ribosomal protein in both cell lines. Metformin (0.1 – 1 mM)
alone decreased phosporylation of S6, whereas it had no effect on total S6 (Figure 6A). Per
densitometric analysis, phosphorylation of S6 was decreased 18–87% for the ECC-1 cell
line and 20–96% for the Ishikawa cell line. In contrast, paclitaxel (0.01 – 10 nM) alone
induced S6 phosphorylation (Figure 6B). Densitometric analysis revealed a 1.3 – 1.8 fold
increase in S6 phosphorylation for the ECC-1 cell line and 1.9 – 7.9 fold increase for the
Ishikawa cell line. The overall effect of the combination of metformin (1 mM) and paclitaxel
(1 nM) differed between the two cell lines. Combination treatment with metformin and
paclitaxel resulted in overall inhibition of S6 phosphorylation in the Ishikawa cell line (81%
decrease by densitometry) whereas induction of S6 phosphorylation was seen in the ECC-1
cell line (2.1 fold increase by densitometry) (Figure 6C). However, in both cell lines,
metformin effectively decreased S6 phosphorylation when compared to that of paclitaxel
alone.
DISCUSSION
We have demonstrated a synergistic relationship between paclitaxel and metformin in
regards to inhibition of cell proliferation and induction of apoptosis in human endometrial
cancer cell lines. Treatment with metformin and paclitaxel resulted in decreased
phosphorylation of S6, a critical downstream target of the mTOR pathway. Metformin
consistently induced AMPK phosphorylation, but the combination of metformin and
paclitaxel had more variable effects on AMPK activation. Additionally, metformin and the
combination of metformin and paclitaxel decreased hTERT mRNA expression, whereas
paclitaxel alone had no effect on telomerase activity. These findings suggest that the
combination of metformin and paclitaxel may be an effective treatment strategy in the
management of endometrial cancer patients.
Synergy was quantified using the CI equation of Chou and Talalay which allows for the
evaluation of two or more chemotherapeutic agents at different concentrations and effect
levels (33). Through this methodology, synergy versus antagonism of various drug
combinations can be analyzed as well as their maximal anti-tumor efficacy. mTOR
inhibitors such as rapamycin are thought to be potent chemotherapeutic chemosensitizers in
many types of cancer cells, including our previous work in endometrial cancer cell lines (30,
39). Given the parallels in the effects of metformin and rapamycin on the mTOR signaling
cascade, it is not surprising that metformin may also behave as a chemosensitizer when used
in combination with cytotoxic agents. We have demonstrated that metformin has the ability
to potentiate the cytotoxic effects of paclitaxel even at low doses of the latter (0.01 – 0.1
nM) (Figure 1). Clinically, this may be important in decreasing toxicities associated with
paclitaxel in endometrial cancer patients without significantly impacting efficacy.
Recent studies in breast, prostate and lung cancer cell lines confirm our work that the
combination of metformin and paclitaxel shows great promise in the management of these
various cancers (40, 41). The combination of metformin with paclitaxel, carboplatin or
doxorubicin has been shown to prolong relapse rate in prostate and lung xenograft models
(40). Most importantly from this study, metformin had comparable effects on tumor
regression and prevention of relapse even when combined with a reduced dose of
doxorubicin that is not usually effective as a monotherapy (40). A subsequent study found
similar results in that metformin and paclitaxel resulted in decreased proliferation via cell
cycle arrest in G2 phase in lung and breast cancer cell lines (41). In this same study, the
combination of paclitaxel and metformin was also found to more effectively decrease tumor
growth and induce apoptosis in a xenograft model of lung cancer as compared to the
individual drug treatments alone (41). To our knowledge, this is the first study to
demonstrate synergy betweem metformin and paclitaxel in endometrial cancer cell lines.
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Treatment with metformin alone results in G1 arrest in the endometrial cancer cell lines. In
contrast, treatment with paclitaxel alone results in G2 arrest as does the combination of
metformin and paclitaxel. These findings mirror that which has been demonstrated in lung
and breast cancer cell lines (41). It is not clear why G2 arrest predominates with metformin
and paclitaxel treatment as opposed to G1 arrest. As we reported previously and in this
work, metformin had minimal effects on apoptosis except at higher doses of treatment (2–5
mM), suggesting that metformin’s anti-tumorigenic effect is more dependent on cell cycle
arrest as opposed to cell death (11). Although 1 mM of metformin did not significantly
induce apoptosis in these endometrial cancer cell lines, treatment with metformin at this
dose and paclitaxel together increased the induction of apoptosis, over that of either agent
alone. The mechanism for this is not well understood. We have found this same
phenomenon for the combination of rapamycin and paclitaxel in endometrial cancer cell
lines and have postulated that this may result from cross talk with the mTOR pathway and
the apoptotic signaling cascade activated by microtubule damage via paclitaxel, possibly
through phosphorylation of the anti-apoptotic Bcl-2 protein (42).
Telomerase activation has been implicated as a fundamental step in cellular immortality and
oncogenesis of many malignancies (43), including endometrial cancers (44, 45). Ninety
percent of endometrial cancers have been found to express telomerase (44). Telomerase
activation, potentially through estrogen stimulation, is thought to be an early step in the
malignant transformation of the endometrium. The first study that linked metformin to the
regulation of telomerase activity was from our laboratory (11), and these findings were
further substantiated in this work. Paclitaxel had no effect on hTERT mRNA expression in
the endometrial cancer cell lines. This is not surprising, given that paclitaxel is known to
induce telomere erosion rather than to regulate telomere activity (46, 47). This erosion
typically occurs before the onset of apoptosis. Interestingly, metformin in combination with
paclitaxel had additive effects on hTERT expression as compared to metformin alone. It can
been hypothesized that the combination of chemotherapeutic agents that interfere with both
telomere structure and telomerase activity, such as metformin and paclitaxel, may ultimately
confer a complementary anti-tumorigenic benefit that is related to regulation of hTERT
mRNA expression that is distinct from their anti-proliferative effects.
As expected, metformin treatment led to the induction of AMPK phosphorylation in a dose-
dependent manner in the endometrial cancer cell lines. Little is known of the effects of
paclitaxel on AMPK phosphorylation. We found that paclitaxel increased AMPK
phosphorylation in one of the endometrial cancer cell lines but not the other. In addition, the
combination of metformin and paclitaxel resulted in greater induction of AMPK
phosphorylation that was more than either agent alone for the ECC-1 cell line. However, this
was not demonstrated in the Ishikawa cell line, although the effects of metformin and
paclitaxel on inhibition of proliferation were similar for both of these cell lines. There is no
readily appreciable difference between these cell lines that would explain these differing
results. Both are derived from women with type 1 endometrial cancers, and both are
estrogen receptor and progesterone receptor positive. To our knowledge, only one other
study has examined the effect of paclitaxel on AMPK and found that paclitaxel increased
AMPK phosphorylation in lung and breast cancer cell lines (41). In this same study, the
combination of metformin and paclitaxel had an additive effect on AMPK phosphorylation,
similar to what we found in the ECC-1 cell line.
Despite the differences in the effect of metformin and paclitaxel on AMPK in the two
endometrial cancer cell lines, the inhibition of the S6 ribosomal protein with this
combination was universal. p70S6K is a critical downstream target of the mTOR pathway
and directly phosphorylates the 40S ribosomal protein S6. This results in enhanced synthesis
of proteins that contain a polypyrimidine tract in the 5’-untranslated region (38). Metformin
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decreased S6 phosphorylation while paclitaxel appeared to increase S6 phosphorylation in
the endometrial cancer cell lines. However, the overall effect with the metformin and
paclitaxel combination was inhibition of S6 phosphorylation as compared to paclitaxel
alone. The effect of paclitaxel on p70S6K and S6 is controversial with seemingly
contradictory results found in regards to induction of p70S6K activity versus inhibition of
phosphosphorylation in breast and ovarian cancer cell lines (41, 48). These findings further
add to this controversy and demonstrate the complexity of effects of treatment with these
agents on the signaling pathways involved as there may be many other pathways that are
also simultaneously regulated.
Alterations in the mTOR pathway have been strongly implicated in endometrial cancer
carcinogenesis. PTEN is a negative regulator of this pathway, and loss of PTEN expression
is one of the most prevalent molecular abnormalities associated with endometrial cancers,
occurring in up to 83% of type I endometrial cancers (49–51). The loss of PTEN expression
may enhance sensitivity of tumor cells to the effects of mTOR inhibitors (52–54), but we
were not able to address this possibility given that Ishikawa and ECC-1 cell lines are both
strongly positive for PTEN (11). In addition, PIK3CA and PIK3R1 mutations have been
reported a high frequency in endometrial cancer tumors (55–57), and PIK3CA mutations
may be associated with increased response rates to PI3K/Akt/mTOR inhibitors (57). Thus,
the mTOR pathway is thought to be a promising target for endometrial cancer treatment, and
mTOR inhibitors are already in clinical trials for this disease. Given the interaction between
metformin and inhibition of the mTOR pathway, there is now growing interest in metformin
for endometrial cancer prevention and treatment, especially for a disease that is so strongly
impacted by obesity and insulin resistance.
Obesity and diabetes have been linked to an increased risk of mortality from endometrial
cancer (4, 58), making metformin a particularly innovative treatment strategy for this
disease. However, the important biological question remains whether metformin will be
universally effective in endometrial cancer treatment or more efficacious in the obese
population. We postulate that the interaction between the tumor and its host environment
(i.e. the obese state) may be critical in endometrial cancer development and progression, and
ultimately, in response to a therapy such as metformin either alone or in combination with
other chemotherapeutic agents. We currently have a preoperative window study of
metformin in endometrial cancer patients that is ongoing that may help to address this
question, and we plan a phase II trial of metformin and paclitaxel that is stratified for obesity
status in this disease. If our hypothesis holds true, this may lead to the individualization of
endometrial cancer treatment based on both tumor biology and the metabolic composition of
the patient.
RESEARCH HIGHLIGHTS
1. Paclitaxel and metformin demonstrated synergy in regards to inhibition of cell
proliferation in human endometrial cancer cell lines.
2. Treatment with metformin and paclitaxel resulted in decreased phosphorylation
of S6, a critical downstream target of the mTOR pathway.
3. These findings suggest that metformin and paclitaxel may be an effective
treatment strategy in endometrial cancer patients.
REFERENCES
1. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer
in Europe. Int J Cancer. 2001; 91(3):421–430. PubMed PMID: 11169969. [PubMed: 11169969]
Hanna et al. Page 9













2. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity:
epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009; 114(1):121–127.
PubMed PMID: 19406460. [PubMed: 19406460]
3. von Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. The impact of obesity and age
on quality of life in gynecologic surgery. Am J Obstet Gynecol. 2005; 193(4):1369–1375. PubMed
PMID: 16202728. [PubMed: 16202728]
4. Chia VM, Newcomb PA, Trentham-Dietz A, Hampton JM. Obesity, diabetes, and other factors in
relation to survival after endometrial cancer diagnosis. Int J Gynecol Cancer. 2007; 17(2):441–446.
PubMed PMID: 17362320. [PubMed: 17362320]
5. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, Rinaldi S, Dossus L, Slimani
N, Lundin E, Tjonneland A, Olsen A, Overvad K, Clavel-Chapelon F, Mesrine S, Joulin V,
Linseisen J, Rohrmann S, Pischon T, Boeing H, Trichopoulos D, Trichopoulou A, Benetou V, Palli
D, Berrino F, Tumino R, Sacerdote C, Mattiello A, Quiros JR, Mendez MA, Sanchez MJ, Larranaga
N, Tormo MJ, Ardanaz E, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Khaw KT, Bingham
S, Allen N, Key T, Jenab M, Riboli E. Plasma adiponectin levels and endometrial cancer risk in pre-
and postmenopausal women. J Clin Endocrinol Metab. 2007; 92(1):255–263. PubMed PMID:
17062769. [PubMed: 17062769]
6. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM,
Lu KH. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;
106(11):2376–2381. PubMed PMID: 16639730. [PubMed: 16639730]
7. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based
prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007; 16(2):276–280. PubMed
PMID: 17301260. [PubMed: 17301260]
8. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC.
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
Science. 2005; 310(5754):1642–1646. PubMed PMID: 16308421. [PubMed: 16308421]
9. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H,
Waldhausl W, Furnsinn C. Thiazolidinediones, like metformin, inhibit respiratory complex I: a
common mechanism contributing to their antidiabetic actions? Diabetes. 2004; 53(4):1052–1059.
PubMed PMID: 15047621. [PubMed: 15047621]
10. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: A new therapeutic opportunity in breast
cancer. Crit Rev Oncol Hematol. 2008 PubMed PMID: 18343152.
11. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent
inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Gynecol Oncol. 2010; 116(1):92–98. PubMed PMID: 19822355; PubMed Central PMCID:
PMC2789879. [PubMed: 19822355]
12. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin
anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008; 110(2):246–250.
PubMed PMID: 18495226. [PubMed: 18495226]
13. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-
dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269–10273.
PubMed PMID: 17062558. [PubMed: 17062558]
14. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on
prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res
(Phila Pa). 2008; 1(5):369–375. PubMed PMID: 19138981.
15. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian
target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007;
67(22):10804–10812. PubMed PMID: 18006825. [PubMed: 18006825]
16. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro
and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576–3586. PubMed
PMID: 18212742. [PubMed: 18212742]
17. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB.
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor
Hanna et al. Page 10













cell growth. Cancer Res. 2007; 67(14):6745–6752. PubMed PMID: 17638885. [PubMed:
17638885]
18. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells,
and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res.
2009; 69(19):7507–7511. PubMed PMID: 19752085. [PubMed: 19752085]
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk
of cancer in diabetic patients. Bmj. 2005; 330(7503):1304–1305. PubMed PMID: 15849206.
[PubMed: 15849206]
20. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for
patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254–
258. PubMed PMID: 16443869. [PubMed: 16443869]
21. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin
are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes
Care. 2009; 32(9):1620–1625. PubMed PMID: 19564453. [PubMed: 19564453]
22. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung
MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to
neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27(20):
3297–3302. PubMed PMID: 19487376. [PubMed: 19487376]
23. Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and
a novel role for metformin. Expert Rev Mol Diagn. 10(4):509–519. PubMed PMID: 20465505.
[PubMed: 20465505]
24. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer.
Clin Cancer Res. 16(6):1695–1700. PubMed PMID: 20215559. [PubMed: 20215559]
25. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin
resistance by mTOR inhibitor in lung cancer. Mol Cancer. 2005; 4(1):25. PubMed PMID:
16033649. [PubMed: 16033649]
26. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting
mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in
breast cancer cells. Clin Cancer Res. 2004; 10(20):7031–7042. PubMed PMID: 15501983.
[PubMed: 15501983]
27. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols
RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-
induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 2007;
13(14):4261–4270. PubMed PMID: 17634556. [PubMed: 17634556]
28. Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Inhibition of the
mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells
to paclitaxel. Eur J Cancer. 2006; 42(7):934–947. PubMed PMID: 16540312. [PubMed:
16540312]
29. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ. Antitumor
activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/
medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;
61(4):1527–1532. PubMed PMID: 11245461. [PubMed: 11245461]
30. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL. Rapamycin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of
apoptosis. Int J Cancer. 2010; 126(5):1144–1154. PubMed PMID: 19688827; PubMed Central
PMCID: PMC2818608. [PubMed: 19688827]
31. Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing
the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther. 2003; 2(8):789–795.
PubMed PMID: 12939469. [PubMed: 12939469]
32. Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M. Quantitation of
hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-
polymerase chain reaction assay. Clin Cancer Res. 2000; 6(2):452–459. PubMed PMID:
10690523. [PubMed: 10690523]
Hanna et al. Page 11













33. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27–55. PubMed PMID:
6382953. [PubMed: 6382953]
34. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, Kamradt JM, Pienta KJ. Signaling
network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology. 1999;
54(4):746–752. PubMed PMID: 10510942. [PubMed: 10510942]
35. Ling YH, Consoli U, Tornos C, Andreeff M, Perez-Soler R. Accumulation of cyclin B1, activation
of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid
carcinoma KB cells treated with taxol. Int J Cancer. 1998; 75(6):925–932. PubMed PMID:
9506539. [PubMed: 9506539]
36. Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an
AMP-kinase dispensable manner. Journal of cellular and molecular medicine. 2011; 15(1):166–
178. PubMed PMID: 19874425. [PubMed: 19874425]
37. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast
cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8(6):
909–915. PubMed PMID: 19221498. [PubMed: 19221498]
38. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses
5'TOP mRNA translation through inhibition of p70s6k. EMBO J. 1997; 16(12):3693–3704.
PubMed PMID: 9218810; PubMed Central PMCID: PMC1169993. [PubMed: 9218810]
39. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in
endometrial cancer cells. Cancer. 2009; 115(17):3887–3896. PubMed PMID: 19484784.
[PubMed: 19484784]
40. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging
tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 71(9):
3196–3201. PubMed PMID: 21415163. [PubMed: 21415163]
41. Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira
JB. Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth.
Clin Cancer Res. 17(12):3993–4005. PubMed PMID: 21543517. [PubMed: 21543517]
42. Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S,
Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require
mTOR and are regulated by Akt. Oncogene. 2004; 23(34):5781–5791. PubMed PMID: 15208671.
[PubMed: 15208671]
43. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol. 2000;
10(6):399–406. PubMed PMID: 11170862. [PubMed: 11170862]
44. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female
reproductive tract and neoplasms. Gynecol Oncol. 1998; 68(2):145–149. PubMed PMID:
9514809. [PubMed: 9514809]
45. Zheng PS, Iwasaka T, Yamasaki F, Ouchida M, Yokoyama M, Nakao Y, Fukuda K, Matsuyama T,
Sugimori H. Telomerase activity in gynecologic tumors. Gynecol Oncol. 1997; 64(1):171–175.
PubMed PMID: 8995569. [PubMed: 8995569]
46. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of
telomeres and telomerase as a cancer therapeutic approach. Cancer Res. 2003; 63(3):579–585.
PubMed PMID: 12566299. [PubMed: 12566299]
47. Multani AS, Li C, Ozen M, Imam AS, Wallace S, Pathak S. Cell-killing by paclitaxel in a
metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease
in telomerase activity. Oncol Rep. 1999; 6(1):39–44. PubMed PMID: 9864398. [PubMed:
9864398]
48. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC Jr. Paclitaxel induces
inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling
pathways in mitosis. Oncogene. 2003; 22(4):484–497. PubMed PMID: 12555062. [PubMed:
12555062]
49. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN
expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;
92(11):924–930. PubMed PMID: 10841828. [PubMed: 10841828]
Hanna et al. Page 12













50. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, Kim SJ. Alteration of PTEN expression in
endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor,
p27. Histopathology. 2002; 41(5):437–445. PubMed PMID: 12405911. [PubMed: 12405911]
51. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation
is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003; 10(2):
203–208. PubMed PMID: 12790783. [PubMed: 12790783]
52. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L,
Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L,
Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten
+/− mice. Proc Natl Acad Sci U S A. 2001; 98(18):10320–10325. PubMed PMID: 11504907.
[PubMed: 11504907]
53. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR
reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res.
2002; 62(21):6141–6145. PubMed PMID: 12414639. [PubMed: 12414639]
54. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H,
Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc
Natl Acad Sci U S A. 2001; 98(18):10314–10319. PubMed PMID: 11504908; PubMed Central
PMCID: PMC56958. [PubMed: 11504908]
55. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85{alpha}) Is
Somatically Mutated at High Frequency in Primary Endometrial Cancer. Cancer Res. 71(12):
4061–4067. PubMed PMID: 21478295. [PubMed: 21478295]
56. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum
of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer
Res. 17(6):1331–1340. PubMed PMID: 21266528. [PubMed: 21266528]
57. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook
GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in
patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther.
10(3):558–565. PubMed PMID: 21216929. [PubMed: 21216929]
58. Steiner E, Plata K, Interthal C, Schmidt M, Faldum A, Hengstler JG, Sakuragi N, Watari H,
Yamamoto R, Kolbl H. Diabetes mellitus is a multivariate independent prognostic factor in
endometrial carcinoma: a clinicopathologic study on 313 patients. European journal of
gynaecological oncology. 2007; 28(2):95–97. PubMed PMID: 17479668. [PubMed: 17479668]
Hanna et al. Page 13













Hanna et al. Page 14













Figure 1. Metformin increased sensitivity to paclitaxel in the ECC-1 and Ishikawa cell lines
The ECC-1 (A) and Ishikawa (B) cells were cultured in the presence of varying
concentrations of paclitaxel (0.001 – 10 nM) and 0.5 mM metformin in regular medium for
48 hours. The inhibition of cell growth was determined by MTT assay. The results are
shown as the mean ± SE of triplicate samples and are representative of 3 independent
experiments. Statistically significant results are marked with an *. (C) Combination Index
(CI) values for the ECC-1 and Ishikawa cell lines treated with metformin and paclitaxel. A
CI of <1 indicates synergy between two chemotherapeutic agents.
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Figure 2. The effect of paclitaxel and metformin on cell cycle progression in the ECC-1 and
Ishikawa cell lines
ECC-1 (A, B, C) and Ishikawa (D, E, F) was cultured for 24 hours and then treated with
different concentrations of paclitaxel (0.1 – 100 nM) and metformin (0.1 – 5 mM) as
indicated for 24 hours. Cell cycle analysis was performed by flow cytometry (M =
metformin; T = paclitaxel). Results shown are representative of two independent
experiments. Treatment with metformin led to G1 arrest whereas treatment with paclitaxel
led to G2 arrest. Combination treatment with both these agents resulted in overall G2 arrest.
The effect of paclitaxel and metformin on cyclin D1 and cyclin B1 expression was also
examined in the Ishikawa and ECC-1 cell lines by Western Immunoblotting. The cells were
treated with paclitaxel (Figure 2G), metformin (Figure 2H) or both in combination (1 mM
metformin and 1nM paclitaxel, Figure 2I) for 48 hours. Paclitaxel treatment resulted in
decreased cyclin D1 and increased cyclin B1 expression. Metformin treatment resulted in
decreased cyclin D1 expression in both cell lines, but only increased cyclin B1 expression in
the ECC-1 cell line. The combination of paclitaxel and metformin treatment led to an overall
increase in cyclin B1 that was greater than the effect of either agent alone. The densitometric
analysis of band intensities, as normalized to the β-actin internal control, is represented
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under each Western blot and signifies the fold increase or decrease in cyclin D1 or cyclin B1
expression.
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Figure 3. Paclitaxel and metformin increases apoptosis in the ECC-1 and Ishikawa cell lines
The ECC-1 (A, B, C) and Ishikawa (D, E, F) cells were cultured for 24 hours and then
treated with different concentrations of paclitaxel (0.1 – 100 nM) and metformin (0.1 – 5
mM) as indicated for 24 hours. Apoptosis was measured by annexin V assay (M =
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metformin; T = paclitaxel). The results are shown as the mean ± SE of two independent
experiments. Statistically significant results are marked with an *.
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Figure 4. Metformin but not paclitaxel decreased hTERT mRNA expression in the ECC-1 (A)
and Ishikawa (B) cell lines. However, there was an additive effect on inhibition of hTERT mRNA
expression when both metformin and paclitaxel were used in combination
Both cell lines were cultured for 24 hours and then treated with the indicated concentrations
of metformin (1 mM) and paclitaxel (1–10 nM) for an additional 24 hours. hTERT
expression was determined by real-time RT-PCR (M = metformin; T = paclitaxel). The
results are shown as the mean ± SE of two independent experiments. Statistically significant
results are marked with an *.
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Figure 5. The effects of metformin and paclitaxel on phosphorylation of AMPK in the Ishikawa
and ECC-1 cell lines
Metformin induced AMPK phosphorylation in a dose-dependent manner in both
endometrial cancer cell lines (A). Paclitaxel induced AMPK phosphorylation in the ECC-1
cell line (B); however, it had no effect on AMPK phosphorylation in the Ishikawa cell line
(B). In the ECC-1 cell line, the combination of paclitaxel (1 nM) and metformin (1 mM)
increased AMPK phosphorylation to more than that of either agent alone (C). This additive
effect on AMPK phosphorylation was not demonstrated in the Ishikawa cell line (C). The
densitometric analysis of band intensities, as normalized to the β-actin internal control, is
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represented under each Western blot and signifies the fold increase or decrease in
phosphorylated AMPK expression. (P-ampk = phosphorylated ampk)
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Figure 6. The effects of paclitaxel and metformin on phosphorylation of S6 in the Ishikawa and
ECC-1 cell lines
The cells were treated with metfomin (A), paclitaxel (B) or both in combination (C) for 24
hrs. Metformin (0.1 – 1 mM) decreased phosphorylation of S6 and paclitaxel (0.01 – 10
mM) increased phosphorylation of S6 in dose dependent manner as determined by Western
immunoblotting. The densitometric analysis of band intensities, as normalized to the β-actin
internal control, is represented under each Western blot and signifies the fold increase or
decrease in phosphorylated S6 expression. (P-S6 = phosphorylated S6)
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